[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "fullTimeEmployees": 22, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 66, "title": "CEO, President, Executive Board Member & Director", "yearBorn": 1957, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.", "age": 69, "title": "Founder, Chief Scientific Officer, Member of Executive Board & Director", "yearBorn": 1954, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1973, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 50, "title": "Chief Operating Officer", "yearBorn": 1973, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jim  Jacobson", "title": "Chief Legal Officer & Secretary", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 56, "title": "Chief Development Officer", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lina  Gugucheva", "age": 36, "title": "Chief Business Officer", "yearBorn": 1987, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sheng  Cui Ph.D.", "title": "VP & Head of Chemistry Manufacturing and Controls (CMC)", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Annie  Neild", "title": "VP & Head of Regulatory Affairs", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William  Jones Jr., M.B.A.", "age": 59, "title": "Chief Commercial Officer", "yearBorn": 1964, "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 2, "previousClose": 8.38, "open": 9.46, "dayLow": 9.35, "dayHigh": 9.46, "regularMarketPreviousClose": 8.38, "regularMarketOpen": 9.46, "regularMarketDayLow": 9.35, "regularMarketDayHigh": 9.46, "beta": -0.09, "volume": 3306, "regularMarketVolume": 3306, "averageVolume": 11867, "averageVolume10days": 27280, "averageDailyVolume10Day": 27280, "bid": 9.3, "ask": 9.46, "bidSize": 1800, "askSize": 4000, "fiftyTwoWeekLow": 0.99, "fiftyTwoWeekHigh": 14.67, "fiftyDayAverage": 4.16474, "twoHundredDayAverage": 2.508175, "currency": "USD", "floatShares": 25552458, "bookValue": 10.838, "priceToBook": 0.8627053, "netIncomeToCommon": -207667008, "52WeekChange": 4.1137724, "SandP52WeekChange": 0.19561028, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "NAMSW", "underlyingSymbol": "NAMSW", "shortName": "NewAmsterdam Pharma Company N.V", "longName": "NewAmsterdam Pharma Company N.V.", "firstTradeDateEpochUtc": 1612967400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "072ede56-783e-317d-b7d9-5dc797a27eef", "messageBoardId": "finmb_685404834", "gmtOffSetMilliseconds": -18000000, "currentPrice": 9.35, "recommendationKey": "none", "totalCash": 383495008, "totalCashPerShare": 4.686, "ebitda": -137619008, "totalDebt": 87000, "quickRatio": 10.004, "currentRatio": 10.154, "totalRevenue": 13562000, "debtToEquity": 0.021, "revenuePerShare": 0.13, "returnOnAssets": -0.2497, "returnOnEquity": -0.68459, "freeCashflow": 124408752, "operatingCashflow": -10247000, "revenueGrowth": -0.898, "grossMargins": 1.0, "operatingMargins": -8.05762, "financialCurrency": "EUR", "trailingPegRatio": null}]